Treatment of Refractory Schizophrenia With Riluzole


Schizoaffective | Schizophrenia

What is the purpose of this trial?

The proposed study would evaluate the benefits of riluzole add-on treatment to patients with schizophrenia who are already receiving medications, but still experience symptoms. Neuroprotective medication riluzole is currently approved for treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease), a severe neurological illness. Due to its unique mechanism of action, riluzole, if effective in helping the symptoms of schizophrenia, would open novel directions in treatment of schizophrenia.

Participation Guidelines

18 Years - 65 Years

Click here for detailed information about who can participate in this trial.

Stanley Medical Research Institute
Yale University
May 2002
Last Updated:
Jan 20, 2009
Study HIC#:
0201013175 ID: NCT00375050